- Roche shares lose after failed Alzheimer's drug test
The first trading session in Europe this week brings modest gains in the indices, which are trying to continue the strong gains initiated by the lower CPI inflation reading in the US. This week we will learn a number of inflation readings from Europe, US PPI inflation data and retail sales data.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe swap market is currently pricing in a near 43% chance of a 75bp rate hike at the ECB's December meeting. Source: Bloomberg
DE30 index chart, D1 interval. The benchmark German blue chips are posting moderate gains today. Source: xStation 5
Monday's German market session brings slightly higher valuations for most economic sectors. Source: Bloomberg
News:
Shares of Merc KGaA (MRK.DE) are trading up sharply on the German stock market today on the back of a raised recommendation on the company's shares by Bofa. Rating of 'buy', target price of €215.
Roche Holding AG (ROG.CH) shares fell more than 3.0% Monday after the Swiss drugmaker announced that its Alzheimer's drug candidate called gantenerumab could not conclusively demonstrate that it slows the progression of dementia. Compared to placebo, the drug showed no statistically significant effect in two studies, the company said.
Bank recommendations:
-
UBS cuts target price for Deutsche Telekom (DTE.DE) shares to 26.4 EUR from previous 27 EUR
Largest percentage changes of companies included in the DAX index. Source: Bloomberg
The most active stocks in the DAX index (DE30). Source: Bloomberg
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
